TreatSMA

MASSIVE NEWS – USA FDA approves risdiplam for broad spectrum of people over 2 months old

We are overjoyed to be able to bring you the news that the FDA has approved risdiplam for the treatment of types 1, 2 and 3 with no age restrictions.

Genentech, a member of the Roche Group, has announced that it has the FDA (Food and Drug Administration) approval in the US to treat adults and children 2 months and older with spinal muscular atrophy.

Evrysdi also known as Risdiplam have done two clinical trials including Types 1, 2, and 3 from Infants to adults up to 25 years of age all with SMA. Both trials have seen vast improvements in all the types and ages that participated.

This is exciting news for us here in the UK as it brings us another step closer to it reaching our community here and others globally.

You can read full details and the press release by clicking here.

Trial details previously announced by TreatSMA for Type 1 and Type 2/3.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more